^
Association details:
| Biomarker: | MSI-H/dMMR + MLH1 deletion + PMS2 deletion |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinically Unsuspected Microsatellite Instability in an Advanced Esophageal Poorly Differentiated Carcinoma
Published date:
10/14/2020
Excerpt:
An 85-year-old woman presented with a high-grade EAC...Additional tissue was requested for immunohistochemistry, which demonstrated a loss of MLH1 and PMS2. Next-generation sequencing confirmed MSI and a high mutation burden. Further analysis identified PD-L1 combined positive score of 21 and nonamplified HER-2. Subsequently, pembrolizumab-based treatment was initiated. After 4 cycles, the primary and metastatic lesions showed marked shrinkage, accompanied by significant symptomatic improvement.
DOI:
https://doi.org/10.5858/arpa.2020-0991-AB
